Skip to main content
BIOCRYST PHARMACEUTICALS INC logo

BIOCRYST PHARMACEUTICALS INC — Investor Relations & Filings

Listed
Ticker · BCRX ISIN · US09058V1035 LEI · 549300Z0INP1Z5NP6J59 US Manufacturing
Open in API
Filings indexed 1,416 across all filing types
Latest filing 2026-06-12 Declaration of Voting R…
Country US United States of America
Listing US BCRX · 10 venues

About BIOCRYST PHARMACEUTICALS INC

https://www.biocryst.com/

BioCryst Pharmaceuticals Inc. is a commercial-stage biotechnology company dedicated to discovering, developing, and commercializing novel medicines for patients with rare and serious diseases. The company's primary focus is on hereditary angioedema (HAE), alongside other rare conditions. BioCryst utilizes its expertise in structure-guided drug design, a process that integrates advanced technologies with biology and medicinal chemistry, to create innovative therapies. It specializes in developing first-in-class or best-in-class oral small-molecule and protein therapeutics, aiming to provide more convenient and effective treatment options for patients.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by BioCryst Pharmaceuticals, Inc. It includes disclosure on matters discussed and voted on at the company's 2026 Annual Meeting of Stockholders, specifically voting results for elections of directors, ratification of auditors, advisory vote on executive compensation, and approval of an amendment to the Stock Incentive Plan. The document is mainly reporting the results of votes held at the Annual Meeting and changes related to the board and officer compensatory arrangements. There are no full financial statements or detailed financial results present. The central content concerns vote outcomes and board/equity plan changes, aligning with changes in board directors or senior officers, and voting results from a shareholders meeting. Therefore, the best fitting filing category is Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-12 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-06 English
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
Regulatory Filings Classification · 82% confidence The document is a Form 8-K current report filed with the SEC under the Securities Exchange Act of 1934, referencing Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure) and furnishing a press release. It is a routine regulatory compliance filing rather than the underlying earnings release itself or any other specific report type. Under the classification scheme, generic SEC filings like 8-Ks fall into the Regulatory Filings category (RNS).
2026-05-06 English
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
Regulatory Filings Classification · 90% confidence The provided text is a Form 8-K Current Report filed with the SEC, disclosing a licensing agreement and incorporating a press release as an exhibit. It does not contain financial statements as a standalone annual or interim report, nor is it an earnings release or proxy. It is a regulatory filing of general corporate news that doesn’t fit other specific categories. Therefore it is classified as a Regulatory Filing (RNS).
2026-05-04 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-04-29 English
ARS
Annual Report
2026-04-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.